Report Overview

The UK Osteoporosis Drugs Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Osteoporosis is defined as a medical condition, which is characterized by low density and quality of bones in humans. Furthermore, the bones become porous in this medical condition, which makes them more fragile and, in turn, prone to factures. The condition is caused by over production of the hormone called as parathyroid. The condition can lead to severe fractures, which can have deleterious effects on the health of patient. Therefore, the condition requires treatment, which includes the use of osteoporosis drugs. Some of the drugs available in the market include bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, and RANK ligand inhibitors.

The market is largely driven by a significant rise in the prevalence of this disorder globally. This unprecedented rise in the prevalence resulted in the high demand for drugs in prophylaxis and treatment of osteoporosis thus widening the growth potential over the coming years. Moreover, the geriatric population possessing high susceptibility for osteoporosis is further presumed to propel the high demand. High R&D investment, fusions, and acquisitions, and drug development agreements are the other strategies incorporated.



Market Drivers

There has been a noticeable growth in people around the country in the awareness of osteoporosis, which is a noticeable factor in the osteoporosis market. This recognition is primarily a result of numerous steps implemented across different programs and campaigns by public and private associations. Moreover, according to National Institutes of Health Osteoporosis and Related Bone Diseases, lifestyle associated factors such as alcohol abuse, sedentary lifestyle, smoking is found to promote this condition in men. The factor poses the high clinical urgency to curb osteoporosis, thus predicted to further bolster the overall growth. The rapid increase in the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care and increasing investment in drug discovery and development are the major factors expected to drive the growth of the market. Rising aging population and post-menopausal women, growing prevalent cases of osteoporosis in younger population, increase expenditures in R&D for new and innovative drug formulation are the other factors supplementing the growth of osteoporosis drugs market.